Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis

Choy, Ernest ORCID: https://orcid.org/0000-0003-4459-8609, Aletaha, Daniel, Behrens, Frank, Finckh, Axel, Gomez-Reino, Juan, Gottenberg, Jacques-Eric, Schuch, Florian and Rubbert-Roth, Andrea 2017. Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Rheumatology 56 (5) , pp. 689-697. 10.1093/rheumatology/kew271

Full text not available from this repository.

Abstract

Current EULAR guidelines state that biologic DMARD (bDMARD) therapy should be administered in combination with MTX or other conventional synthetic (cs) DMARD in RA. Nonetheless, a third of patients for whom a bDMARD agent is prescribed take it in the absence of concurrent csDMARD therapy. While the reasons underlying the low uptake of bDMARD–csDMARD combination therapy in clinical practice have not been well delineated, they may include poor adherence, contraindication to csDMARD therapy and adverse effects, as well as csDMARD withdrawal following remission. The challenges surrounding bDMARD therapy and the benefit/risk ratio of biologic monotherapy when compared with combination with a csDMARD will be discussed. We will provide insights into these important issues, as well as reviewing the evidence base differentiating biologic agents and exploring therapeutic options for patients with rheumatoid arthritis for whom csDMARD therapy is contraindicated or discontinued.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Oxford University Press
ISSN:	1462-0324
Last Modified:	02 Nov 2022 11:32
URI:	https://orca.cardiff.ac.uk/id/eprint/102378

Citation Data

Cited 20 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item